LTZ Therapeutics received FDA IND clearance for LTZ-232, enabling the start of a Phase 1 study in advanced metastatic colorectal cancer and other solid tumors. The clearance marks a key regulatory step for the company’s clinical progression from preclinical to first-in-human testing. The move also signals continued interest in novel small-molecule or targeted oncology strategies entering early-stage oncology cohorts. If successful, LTZ-232 could contribute to expanding options for hard-to-treat metastatic settings while providing early safety and dose-optimization data. For investors and trial operators, the IND clearance de-risks timelines to enrollment and supports planning for initial dose-finding and expansion cohorts.